Loading patent…
AssigneesTrustees of Boston University, Massachusetts Institute of Technology
InventorsJames J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Tanguy My Chau, Gregory Stephanopoulos, Christopher Jongsoo Yoon
Estimating the term…
The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
An engineered bacteriophage comprising a heterologous nucleic acid operatively linked to a promoter, wherein the nucleic acid encodes at least one antimicrobial polypeptide fused to an N-terminal secretory signal sequence, the antimicrobial peptide having antimicrobial properties when outside a bacterial cell.
An engineered bacteriophage comprising a heterologous nucleic acid operatively linked to a promoter, the nucleic acid encoding an antimicrobial peptide (AMP) of 12 to 50 amino acids in length fused to an N-terminal bacterial secretion signal sequence, the AMP having antimicrobial properties when outside a bacterial cell.
Dependencies are inferred from the claim text.